Skip to main content
. 2021 Nov 23;2021:3928323. doi: 10.1155/2021/3928323

Figure 3.

Figure 3

Mouse pyroptosis pathway regulators. (a) Schematic representation of canonical vs. noncanonical pyroptosis. (b) Mouse canonical inflammasome pathway regulators (90 genes, KEGG pathway hsa04621) were differentially expressed in NASH/NAFLD models. The MCD+HFD model upregulated 18 out of 90 (20%) canonical inflammasome pathway regulators including caspase-1 and downregulated 11 out of 90 (12.2%) canonical inflammasome pathway regulators. The MAT1A-KO model upregulated 5 out of 90 (5.6%) and downregulated 4 out of 90 (4.4%) canonical inflammasome pathway regulators. The GNMT-KO model upregulated 1 out of 90 (1.1%) and downregulated 2 out of 90 (2.2%) canonical inflammasome pathway regulators. The HFCD model upregulated 7 out of 90 (7.8%) and downregulated 26 out of 90 (28.9%) canonical inflammasome pathway regulators. (c) Mouse noncanonical inflammasome pathway regulators (14 genes, KEGG pathway hsa04621) were differentially expressed in NASH/NAFLD. The MCD+HFD model upregulated zero out of 14 (0%) and downregulated 6 out of 14 (42.8%) noncanonical inflammasome pathway regulators. The MAT1A-KO model upregulated 3 out of 14 (21.4%) and downregulated 3 out of 14 (21.4%) noncanonical inflammasome pathway regulators. The GNMT-KO model upregulated 0 out of 14 (0%) and downregulated 1 out of 14 (7.1%) noncanonical inflammasome pathway regulators. The HFCD model upregulated 1 out of 14 (7.1%) and downregulated 9 out of 14 (64.3%) noncanonical inflammasome pathway regulators.